ArticleHLA2026
Fine-Mapping of HLA Effects in Oral and Non-Oral Lichen Planus.
Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lichen planus (LP) is an inflammatory disease affecting squamous epithelia, typically manifesting in a cutaneous (non-OLP) and an oral mucosa (OLP) form, the latter conferring elevated risk of oral squamous cell carcinoma. Despite the presence of CD4+ and CD8+ T-cell infiltrates in LP lesions, specific autoantibodies or target T-cell antigens have not been identified. A recent genome-wide association study (GWAS) uncovered 27 genome-wide independent associations, with the strongest signal within HLA Class II, particularly involving DQB1*05:01. This association showed stronger effects in non-OLP (OR = 2.09) versus OLP (OR = 1.36). Here, we performed a high-resolution HLA fine-mapping analysis in FinnGen to dissect this strong Class II signal and clarify its relationship to LP subtypes. We find that most DQA1*01~DQB1*05:01 haplotypes confer increased susceptibility, with the highest risk conferred by DQA1*01:05~DQB1*05:01 followed by DQA1*01:01~DQB1*05:01. In subjects not carrying DQB1*05:01, DRB1*15:01~DQA1*01:02~DQB1*06:02 had a strong protective effect, more pronounced in non-OLP than OLP. Further associations were found with DRB1*09:01 and DQB1*02:02 as well as independent HLA Class I associations with A*03:01, B*08:01 and B*13:02, all stronger in OLP versus non-OLP. Conditioning SNP associations for these effects eliminated the HLA GWAS signal. These effects highlight that while the DQB1*05:01 association remains largely invariant to DQA1 polymorphisms across LP subtypes, the variable strength of HLA associations in non-OLP and OLP forms suggests distinct immunopathological mechanisms. The presence of strong trans-heterodimer effects in this disease illustrates the need to analyse HLA-DQ-associated diseases with methods beyond simple conditioning. The invariance to DQA1 polymorphisms in LP may facilitate the identification of potential pathological epitopes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.